Alzheimer Hastalığında miRNA’lar ve Etkileri
Özet
Alzheimer Hastalığı (AH), yaşlanma ile birlikte en yaygın görülen nörodejeneratif hastalıklardan biridir ve demansın en sık nedeni olarak kabul edilmektedir. AH, bilişsel işlevlerin ilerleyici kaybı, hafıza bozuklukları ve davranışsal değişikliklerle karakterizedir. Günümüzde kesin bir tedavisi bulunmamakla birlikte, hastalığın altında yatan moleküler mekanizmaların anlaşılması, etkili tedavi stratejilerinin geliştirilmesi açısından büyük önem taşımaktadır.
Son yıllarda, AH’nin patogenezinde genetik ve epigenetik düzenleyicilerin önemli bir rol oynadığı gösterilmiştir. Bu bağlamda, mikroRNA’lar (miRNA’lar) gibi küçük, kodlanmayan RNA moleküllerinin, gen ekspresyonunu post-transkripsiyonel seviyede düzenleyerek hastalığın ilerleyişine katkıda bulunduğu anlaşılmıştır. miRNA’ların, nörodejeneratif hastalıkların biyolojik süreçlerinde yer aldığına dair kanıtlar artmakta olup, özellikle AH’nin patofizyolojisi üzerindeki etkileri giderek daha fazla araştırılmaktadır. miRNA'lardaki değişikliklerin, hastalığa özgü nöropatolojik oluşumlar, beyinde amiloid plaklar, nörofibriler yumaklar ve AH ile ilişkili bazı moleküllerin ekspresyon seviyeleriyle bağlantılı olduğu bulunmuştur. miRNA'ların işlevlerinin daha iyi anlaşılması hem AH'nin moleküler mekanizmalarının aydınlatılmasına hem de erken teşhis için biyobelirteç olarak değerlendirilmesine katkı sağlayabilir. Ayrıca, miRNA'ların terapötik hedefler olarak değerlendirilmesi, AH tedavisine yönelik yeni yaklaşımlar geliştirilmesine yardımcı olabilir.
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders associated with aging and is considered the leading cause of dementia. AD is characterized by progressive cognitive decline, memory impairment, and behavioral changes. Although no definitive cure currently exists, understanding the underlying molecular mechanisms of the disease is crucial for developing effective therapeutic strategies.
In recent years, genetic and epigenetic regulators have been shown to play significant roles in the pathogenesis of AD. In this context, microRNAs (miRNAs), which are small non-coding RNA molecules, have been found to contribute to disease progression by regulating gene expression at the post-transcriptional level. Evidence supporting the involvement of miRNAs in the biological processes of neurodegenerative diseases is steadily increasing, with growing interest in their specific impact on the pathophysiology of AD.
Alterations in miRNA expression have been linked to neuropathological features characteristic of AD, such as amyloid plaques, neurofibrillary tangles, and the dysregulation of molecules associated with the disease. A deeper understanding of miRNA functions may aid in elucidating the molecular mechanisms of AD and in evaluating miRNAs as potential biomarkers for early diagnosis. Furthermore, considering miRNAs as therapeutic targets could pave the way for the development of novel treatment approaches for Alzheimer’s disease.
Referanslar
Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly--an update. J Alzheimers Dis. 2006;9(3 Suppl):61-70. doi: 10.3233/jad-2006-9s308. PMID: 16914845.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. PMID: 21514250; PMCID: PMC3312024.
Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013 May 7;80(19):1778-83. doi: 10.1212/WNL.0b013e31828726f5. Epub 2013 Feb 6. PMID: 23390181; PMCID: PMC3719424.
Willem M, Garratt AN, Novak B, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006 Oct 27;314(5799):664-6. doi: 10.1126/science.1132341. Epub 2006 Sep 21. PMID: 16990514.
Zhang X, Li Y, Xu H, et al. The γ-secretase complex: from structure to function. Front Cell Neurosci. 2014 Dec 11;8:427. doi: 10.3389/fncel.2014.00427. PMID: 25565961; PMCID: PMC4263104.
Cook DG, Forman MS, Sung JC, et al. Alzheimer's A beta (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med. 1997 Sep;3(9):1021-3. doi: 10.1038/nm0997-1021. PMID: 9288730.
Greenfield JP, Tsai J, Gouras GK, et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):742-7. doi: 10.1073/pnas.96.2.742. PMID: 9892704; PMCID: PMC15207.
Tanabe C, Hotoda N, Sasagawa N, et al. ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells. Biochem Biophys Res Commun. 2007 Jan 5;352(1):111-7. doi: 10.1016/j.bbrc.2006.10.181. Epub 2006 Nov 9. PMID: 17112471.
Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003 Jan 6;160(1):113-23. doi: 10.1083/jcb.200207113. Epub 2003 Jan 6. PMID: 12515826; PMCID: PMC2172747.
Igbavboa U, Eckert GP, Malo TM, et al. Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE 3 and 4 and by increasing age. J Neurol Sci. 2005 Mar 15;229-230:225-32. doi: 10.1016/j.jns.2004.11.037. Epub 2004 Dec 16. PMID: 15760644.
Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11;32(18):4693-7. doi: 10.1021/bi00069a001. PMID: 8490014.
Chen W, Gamache E, Rosenman DJ, et al. Familial Alzheimer's mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat Commun. 2014; 5:3037. doi: 10.1038/ncomms4037. PMID: 24390130; PMCID: PMC4082030.
Spies PE, Slats D, Sjögren JM, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res. 2010 Aug;7(5):470-6. doi: 10.2174/156720510791383796. PMID: 20043812.
Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004 Nov 10;24(45):10191-200. doi: 10.1523/JNEUROSCI.3432-04.2004. PMID: 15537891; PMCID: PMC6730194.
Buée L, Bussière T, Buée-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000 Aug;33(1):95-130. doi: 10.1016/s0165-0173(00)00019-9. PMID: 10967355.
Harada A, Oguchi K, Okabe S, et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994 Jun 9;369(6480):488-91. doi: 10.1038/369488a0. PMID: 8202139.
Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci. 2004 Nov 15;117(Pt 24):5721-9. doi: 10.1242/jcs.01558. PMID: 15537830.
Hardy J. The relationship between amyloid and tau. J Mol Neurosci. 2003 Apr;20(2):203-6. doi: 10.1385/JMN:20:2:203. PMID: 12794314.
Zhang F, Jiang L. Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat. 2015 Jan 30; 11:243-56. doi: 10.2147/NDT.S75546. PMID: 25673992; PMCID: PMC4321665.
Hartlage-Rübsamen M, Zeitschel U, Apelt J, et al. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia. 2003 Jan 15;41(2):169-79. doi: 10.1002/glia.10178. PMID: 12509807.
Sze CI, Troncoso JC, Kawas C, et al. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997 Aug;56(8):933-44. doi: 10.1097/00005072-199708000-00011. PMID: 9258263.
Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005 Apr;7(2):103-17; discussion 173-80. doi: 10.3233/jad-2005-7203. PMID: 15851848.
Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009 Nov 23;4:48. doi: 10.1186/1750-1326-4-48. PMID: 19930651; PMCID: PMC2788538.
Walsh DM, Townsend M, Podlisny MB, et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005 Mar 9;25(10):2455-62. doi: 10.1523/JNEUROSCI.4391-04.2005. Erratum in: J Neurosci. 2005 May 4;25(18):4658. PMID: 15758153; PMCID: PMC6725159.
Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009 Jul 16;361(3):302-3. doi: 10.1056/NEJMcibr0902052. PMID: 19605837; PMCID: PMC3703758.
Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005 Aug;8(8):1051-8. doi: 10.1038/nn1503. Epub 2005 Jul 17. PMID: 16025111.
Hsieh H, Boehm J, Sato C, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006 Dec 7;52(5):831-43. doi: 10.1016/j.neuron.2006.10.035. PMID: 17145504; PMCID: PMC1850952.
Wang HY, Lee DH, D'Andrea MR, et al. Beta -Amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem. 2000 Feb 25;275(8):5626-32. doi: 10.1074/jbc.275.8.5626. PMID: 10681545.
Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci. 2007 Mar 7;27(10):2628-35. doi: 10.1523/JNEUROSCI.5053-06.2007. PMID: 17344400; PMCID: PMC6672502.
Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011 Mar 19;377(9770):1019-31. doi: 10.1016/S0140-6736(10)61349-9. Epub 2011 Mar 1. PMID: 21371747.
O'Brien J, Hayder H, Zayed Y, et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018 Aug 3; 9:402. doi: 10.3389/fendo.2018.00402. PMID: 30123182; PMCID: PMC6085463.
Wahid F, Shehzad A, Khan T, et al. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010 Nov;1803(11):1231-43. doi: 10.1016/j.bbamcr.2010.06.013. Epub 2010 Jul 7. PMID: 20619301.
Starega-Roslan J, Koscianska E, Kozlowski P, et al. The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci. 2011 Sep;68(17):2859-71. doi: 10.1007/s00018-011-0726-2. Epub 2011 May 24. PMID: 21607569; PMCID: PMC3155042.
Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004 Feb;10(2):185-91. doi: 10.1261/rna.5167604. PMID: 14730017; PMCID: PMC1370530.
Ambrus AM, Frolov MV. The diverse roles of RNA helicases in RNAi. Cell Cycle. 2009 Nov 1;8(21):3500-5. doi: 10.4161/cc.8.21.9887. Epub 2009 Nov 24. PMID: 19823018; PMCID: PMC3016640.
Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019 Jan;20(1):5-20. doi: 10.1038/s41580-018-0059-1. Erratum in: Nat Rev Mol Cell Biol. 2018 Dec;19(12):808. doi: 10.1038/s41580-018-0070-6. Erratum in: Nat Rev Mol Cell Biol. 2019 May;20(5):321. doi: 10.1038/s41580-019-0106-6. PMID: 30228348.
van den Berg A, Mols J, Han J. RISC-target interaction: cleavage and translational suppression. Biochim Biophys Acta. 2008 Nov;1779(11):668-77. doi: 10.1016/j.bbagrm.2008.07.005. Epub 2008 Jul 22. PMID: 18692607; PMCID: PMC2646505.
Liu CG, Song J, Zhang YQ, et al. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. Mol Med Rep. 2014 Nov;10(5):2395-400. doi: 10.3892/mmr.2014.2484. Epub 2014 Aug 12. PMID: 25119742.
Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008 May 23;30(4):460-71. doi: 10.1016/j.molcel.2008.05.001. PMID: 18498749.
Li YB, Fu Q, Guo M, et al. MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy. Transl Psychiatry. 2024 Sep 10;14(1):367. doi: 10.1038/s41398-024-03075-8. PMID: 39256358; PMCID: PMC11387755.
Bhattacharyya NP, Das E, Bucha S, et al. Regulation of Cell Cycle Associated Genes by microRNA and Transcription Factor. Microrna. 2016;5(3):180-200. doi: 10.2174/2211536605666161117112251. PMID: 27855605.
Liu B, Shyr Y, Cai J, et al. Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics. 2018 Jul 22;18(4):255-266. doi: 10.1093/bfgp/elz002. PMID: 30785618; PMCID: PMC6609535.
Smith-Vikos T, Slack FJ. MicroRNAs and their roles in aging. J Cell Sci. 2012 Jan 1;125(Pt 1):7-17. doi: 10.1242/jcs.099200. PMID: 22294612; PMCID: PMC3269020.
Patel N, Hoang D, Miller N, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener. 2008 Aug 6; 3:10. doi: 10.1186/1750-1326-3-10. PMID: 18684319; PMCID: PMC2529281.
Hébert SS, Horré K, Nicolaï L, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis. 2009 Mar;33(3):422-8. doi: 10.1016/j.nbd.2008.11.009. Epub 2008 Dec 9. PMID: 19110058.
Vilardo E, Barbato C, Ciotti M, et al. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem. 2010 Jun 11;285(24):18344-51. doi: 10.1074/jbc.M110.112664. Epub 2010 Apr 15. PMID: 20395292; PMCID: PMC2881760.
Liu W, Liu C, Zhu J, et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol Aging. 2012 Mar;33(3):522-34. doi: 10.1016/j.neurobiolaging.2010.04.034. Epub 2010 Jul 8. PMID: 20619502.
Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem. 2012 Sep 7;287(37):31298-310. doi: 10.1074/jbc.M112.366336. Epub 2012 Jun 25. PMID: 22733824; PMCID: PMC3438960.
Yang LB, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003 Jan;9(1):3-4. doi: 10.1038/nm0103-3. PMID: 12514700.
Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23. PMID: 18434550; PMCID: PMC2359789.
Lei X, Lei L, Zhang Z, et al. Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1565-74. PMID: 25973041; PMCID: PMC4396232.
Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008 Jan 30;28(5):1213-23. doi: 10.1523/JNEUROSCI.5065-07.2008. PMID: 18234899; PMCID: PMC2837363.
Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimers Dis. 2010;21(1):75-9. doi: 10.3233/JAD-2010-091603. PMID: 20413881; PMCID: PMC2910235.
Liu W, Cai H, Lin M, et al. MicroRNA-107 prevents amyloid-beta induced blood-brain barrier disruption and endothelial cell dysfunction by targeting Endophilin-1. Exp Cell Res. 2016 May 1;343(2):248-257. doi: 10.1016/j.yexcr.2016.03.026. Epub 2016 Mar 30. PMID: 27038654.
Shu B, Zhang X, Du G, et al. MicroRNA-107 prevents amyloid-β-induced neurotoxicity and memory impairment in mice. Int J Mol Med. 2018 Mar;41(3):1665-1672. doi: 10.3892/ijmm.2017.3339. Epub 2017 Dec 22. PMID: 29286086.
Parsi S, Smith PY, Goupil C, et al. Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease. Mol Ther Nucleic Acids. 2015 Oct 6;4(10): e256. doi: 10.1038/mtna.2015.33. PMID: 26440600; PMCID: PMC4881761.
Boissonneault V, Plante I, Rivest S, et al. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem. 2009 Jan 23;284(4):1971-81. doi: 10.1074/jbc.M807530200. Epub 2008 Nov 5. PMID: 18986979; PMCID: PMC2908704.
Zhu HC, Wang LM, Wang M, et al. MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res Bull. 2012 Sep 1;88(6):596-601. doi: 10.1016/j.brainresbull.2012.05.018. Epub 2012 Jun 19. PMID: 22721728.
Liu CG, Wang JL, Li L, et al. MicroRNA-135’a and -200b, potential Biomarkers for Alzheimer׳s disease, regulate β secretase and amyloid precursor protein. Brain Res. 2014 Oct 2; 1583:55-64. doi: 10.1016/j.brainres.2014.04.026. Epub 2014 Aug 22. PMID: 25152461.
Zhang Y, Xing H, Guo S, et al. MicroRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1. Exp Ther Med. 2016 Aug;12(2):809-814. doi: 10.3892/etm.2016.3366. Epub 2016 May 19. PMID: 27446280; PMCID: PMC4950157.
Long JM, Ray B, Lahiri DK. MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem. 2014 Feb 21;289(8):5184-98. doi: 10.1074/jbc.M113.518241. Epub 2013 Dec 18. PMID: 24352696; PMCID: PMC3931075.
Kim J, Yoon H, Chung DE, et al. miR-186 is decreased in aged brain and suppresses BACE1 expression. J Neurochem. 2016 May;137(3):436-45. doi: 10.1111/jnc.13507. Epub 2016 Mar 30. PMID: 26710318; PMCID: PMC4837067.
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007 Sep;8(9):663-72. doi: 10.1038/nrn2194. PMID: 17684513.
Wang M, Qin L, Tang B. MicroRNAs in Alzheimer's Disease. Front Genet. 2019 Mar 1; 10:153. doi: 10.3389/fgene.2019.00153. PMID: 30881384; PMCID: PMC6405631.
Jin Y, Tu Q, Liu M. MicroRNA 125b regulates Alzheimer's disease through SphK1 regulation. Mol Med Rep. 2018 Aug;18(2):2373-2380. doi: 10.3892/mmr.2018.9156. Epub 2018 Jun 13. PMID: 29901156.
Banzhaf-Strathmann J, Benito E, May S, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. EMBO J. 2014 Aug 1;33(15):1667-80. doi: 10.15252/embj.201387576. Epub 2014 Jul 7. PMID: 25001178; PMCID: PMC4194100.
Ma X, Liu L, Meng J. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer's disease. Neurosci Lett. 2017 Nov 20; 661:57-62. doi: 10.1016/j.neulet.2017.09.043. Epub 2017 Sep 22. Retraction in: Neurosci Lett. 2022 Jul 13; 783:136703. doi: 10.1016/j.neulet.2022.136703. PMID: 28947385.
Smith PY, Hernandez-Rapp J, Jolivette F, et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet. 2015 Dec 1;24(23):6721-35. doi: 10.1093/hmg/ddv377. Epub 2015 Sep 11. PMID: 26362250; PMCID: PMC4634376.
Wang Y, Veremeyko T, Wong AH, et al. Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease. Neurobiol Aging. 2017 Mar; 51:156-166. doi: 10.1016/j.neurobiolaging.2016.12.015. Epub 2016 Dec 27. PMID: 28089352.
El Fatimy R, Li S, Chen Z, et al. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018 Oct;136(4):537-555. doi: 10.1007/s00401-018-1880-5. Epub 2018 Jul 7. PMID: 29982852; PMCID: PMC6132948.
Wang X, Tan L, Lu Y, et al. MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. 2015 Mar 12;589(6):726-9. doi: 10.1016/j.febslet.2015.02.001. Epub 2015 Feb 11. PMID: 25680531.
Absalon S, Kochanek DM, Raghavan V, et al. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013 Sep 11;33(37):14645-59. doi: 10.1523/JNEUROSCI.1327-13.2013. PMID: 24027266; PMCID: PMC3810537.
Zhao ZB, Wu L, Xiong R, et al. MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer's disease. Neuroscience. 2014 Sep 5; 275:232-7. doi: 10.1016/j.neuroscience.2014.06.013. Epub 2014 Jun 17. PMID: 24950120.
Wang G, Huang Y, Wang LL, et al. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. Sci Rep. 2016 May 25; 6:26697. doi: 10.1038/srep26697. PMID: 27221467; PMCID: PMC4879631.
Liu W, Zhao J, Lu G. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease. Biochem Biophys Res Commun. 2016 Sep 16;478(2):852-7. doi: 10.1016/j.bbrc.2016.08.037. Epub 2016 Aug 9. PMID: 27520374.
Kang Q, Xiang Y, Li D, et al. MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3β pathway in N2a/APP695swe cells. Oncotarget. 2017 Apr 11;8(15):24314-24326. doi: 10.18632/oncotarget.15149. PMID: 28186985; PMCID: PMC5421849.
Liang C, Zou T, Zhang M, et al. MicroRNA-146a switches microglial phenotypes to resist the pathological processes and cognitive degradation of Alzheimer's disease. Theranostics. 2021 Feb 19;11(9):4103-4121. doi: 10.7150/thno.53418. PMID: 33754051; PMCID: PMC7977456.
Huang Y, Lin X, Lin X. MiR-146a-5p Contributes to Microglial Polarization Transitions Associated With AGEs. Mol Neurobiol. 2023 Jun;60(6):3020-3033. doi: 10.1007/s12035-023-03252-8. Epub 2023 Feb 13. PMID: 36780120.
Redis RS, Calin S, Yang Y, et al. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012 Nov;136(2):169-74. doi: 10.1016/j.pharmthera.2012.08.003. Epub 2012 Aug 8. PMID: 22903157; PMCID: PMC3855335.
Zhang G, Liu Y, Xu L, et al. Resveratrol alleviates lipopolysaccharide-induced inflammation in PC-12 cells and in rat model. BMC Biotechnol. 2019 Jan 28;19(1):10. doi: 10.1186/s12896-019-0502-1. PMID: 30691440; PMCID: PMC6350285.
Rastegar-Moghaddam SH, Ebrahimzadeh-Bideskan A, Shahba S, et al. Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target. Cell Mol Neurobiol. 2023 Mar;43(2):455-467. doi: 10.1007/s10571-022-01200-z. Epub 2022 Feb 2. PMID: 35107690.
Yin Z, Herron S, Silveira S, et al. Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer's disease. Nat Neurosci. 2023 Jul;26(7):1196-1207. doi: 10.1038/s41593-023-01355-y. Epub 2023 Jun 8. PMID: 37291336; PMCID: PMC10619638.
Song J, Lee JE. miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function. Front Aging Neurosci. 2015 Apr 30; 7:61. doi: 10.3389/fnagi.2015.00061. PMID: 25983691; PMCID: PMC4415416.
Remenyi J, van den Bosch MW, Palygin O, et al. miR-132/212 knockout mice reveal roles for these miRNAs in regulating cortical synaptic transmission and plasticity. PLoS One. 2013 Apr 26;8(4):e62509. doi: 10.1371/journal.pone.0062509. PMID: 23658634; PMCID: PMC3637221.
Wingo TS, Yang J, Fan W, et al. Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia. NPJ Genom Med. 2020 Feb 6; 5:6. doi: 10.1038/s41525-019-0113-8. PMID: 32047652; PMCID: PMC7004995.
Hu S, Wang H, Chen K, et al. MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2. J Alzheimers Dis. 2015;48(3):673-86. doi: 10.3233/JAD-150432. PMID: 26402112.
Xu Y, Chen P, Wang X, et al. miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors. Neurosci Lett. 2018 Mar 23; 670:94-104. doi: 10.1016/j.neulet.2018.01.045. Epub 2018 Feb 6. PMID: 29378298.
Lee K, Kim H, An K, et al. Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD Mouse Model of Alzheimer's Disease. Sci Rep. 2016 Oct 6; 6:34433. doi: 10.1038/srep34433. PMID: 27708404; PMCID: PMC5052619.
Wu BW, Wu MS, Guo JD. Effects of microRNA-10a on synapse remodeling in hippocampal neurons and neuronal cell proliferation and apoptosis through the BDNF-TrkB signaling pathway in a rat model of Alzheimer's disease. J Cell Physiol. 2018 Jul;233(7):5281-5292. doi: 10.1002/jcp.26328. Epub 2018 Jan 19. Retraction in: J Cell Physiol. 2022 Feb;237(2):1623. doi: 10.1002/jcp.30476. PMID: 29215712.
Wang X, Liu D, Huang HZ, et al. A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease. Biol Psychiatry. 2018 Mar 1;83(5):395-405. doi: 10.1016/j.biopsych.2017.07.023. Epub 2017 Aug 10. PMID: 28965984.
